Oncologists' Response to New Data Regarding the Use of Epidermal Growth Factor Receptor Inhibitors in Colorectal Cancer

PURPOSE: Although initially approved for metastatic colorectal cancer (mCRC) tumors with epidermal growth factor receptor (EGFR) overexpression, the use of anti-EGFR antibodies is now restricted to wild-type KRAS tumors. Little is known about prescribers' response to new clinical data, practice...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Dotan, Efrat, Li, Tianyu, Hall, Michael J., Meropol, Neal J., Beck, J. Robert, Wong, Yu-Ning
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2014
Matèries:
Health Care Delivery
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4161728/
https://ncbi.nlm.nih.gov/pubmed/25052499
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JOP.2014.001439
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars